The Opportunity Oncofibro is a commercial-stage biotech company founded and deeply rooted by scientists-developing advanced therapies for both human health and companion animal health to unlock life-improving medicines where unmet needs remain high. We begin with serious chronic lung disorders, building innovative therapies designed to keep T cells effective-supporting immune persistence when chronic disease can blunt the body's natural defenses. Our portfolio includes Krysaygio™, an autologous ex vivo cell therapy undergoing clinical evaluation, Treactivus™, a direct injectable immunotherapy for veterinary use, and Tatmyctotrans™, an ancillary starting raw material designed to recondition exhausted immune cells pre-expansion for more effective autologous cell therapy manufacturing.
We continuously invest in meeting unmet clinical needs by unlocking the bottlenecks that slow translation from promising biology to practical care-beginning in lung disease, with the potential to expand ...